Israel's VBL Therapeutics hit with CMC delays in ovarian cancer study; Novo Holdings buys out diagnostics player BBI
VBL Therapeutics has hit a roadblock in its Phase III study for platinum-resistant ovarian cancer.
Batches of the VB-111 compound being evaluated in the study are still being reviewed by the FDA’s CMC group, the company announced Tuesday, with regulators trying to compare VB-111 manufacturing between different sites. As a result, supply will be limited and VBL is pausing enrollment of the 400-patient study until the batches can be cleared.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.